Autologous cultured chondrocytes on porcine collagen membrane
| Autologous cultured chondrocytes on porcine collagen membrane | |
|---|---|
| Other names | MACI |
| Specialty | orthopedic |
| Clinical data | |
|---|---|
| Trade names | Maci |
| License data | |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| DrugBank | |
| UNII | |
Autologous cultured chondrocytes on porcine collagen membrane (Maci) is a treatment to correct cartilage defects in the knee.[1] It is used to treat symptomatic, full-thickness cartilage defects of the knee with or without bone involvement.[2][1] Autologous cultured chondrocytes on porcine collagen membrane is an autologous cellularized scaffold product.[1] This treatment is approved by the US Food and Drug Administration (FDA).[1] It is only administered to adults.[1] Healthy cartilage is removed from the person's own knees and a 'scaffold' is created on which the healthy tissue growths.[1] This is an autologous matrix-induced chondrogenesis procedure which prevents tissue rejection complications since the transplanted cartilage comes from the same person.[3]
Autologous cultured chondrocytes on porcine collagen membrane was approved for use in the United States in May 2019.[2]
See also[edit]
References[edit]
- ^ a b c d e f g "Maci- autologous cultured chondrocytes implant". DailyMed. 23 October 2019. Retrieved 1 April 2020.
- ^ a b c "Maci (Autologous Cultured Chondrocytes on a Porcine Collagen Membrane)". U.S. Food and Drug Administration (FDA). Retrieved 13 May 2017.
This article incorporates text from this source, which is in the public domain.
- ^ Megan B (December 14, 2016). "FDA Clears Novel Scaffold for Knee Cartilage Repair". Medscape. Retrieved 13 May 2017.
 | This medical treatment–related article is a stub. You can help Wikipedia by expanding it. |